SCHEMBL10312118

SCHEMBL10312118

Cc1cc(Nc2nc(/C=C/c3cccc(Cl)c3)nc(NCCCN3CCOCC3)n2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.46
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
MAPT P10636 1/20 0.44
AURKA O14965 4/20 0.43
KDR P35968 3/20 0.42
GRK6 P43250 1/20 0.42
PLK4 O00444 3/20 0.42
NTRK1 P04629 3/20 0.42
FGFR1 P11362 3/20 0.42
SRC P12931 3/20 0.42
ABL1 P00519 2/20 0.42
LCK P06239 2/20 0.42
CSF1R P07333 2/20 0.42
RET P07949 2/20 0.42
KIT P10721 2/20 0.42
PDGFRA P16234 2/20 0.42
TYK2 P29597 2/20 0.42
PTK2 Q05397 2/20 0.42
AURKB Q96GD4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312149 0.91 FLT3 (0.45) FLT3GSK3AGSK3BMAPTKDR
SCHEMBL10312201 0.91 FLT3 (0.46) FLT3GSK3AGSK3BAURKAKDR
SCHEMBL16556851 0.88 IGF1R (0.46) FLT3GSK3AGSK3BMAPTKDR
SCHEMBL10312176 0.88 MELK (0.46) FLT3GSK3AGSK3BAURKAKDR
SCHEMBL10312193 0.85 AURKA (0.41) FLT3GSK3AGSK3BAURKAKDR
SCHEMBL10312104 0.82 NTRK1 (0.54) FLT3GSK3AGSK3BMAPTAURKA
SCHEMBL10312150 0.82 IGF1R (0.48) FLT3NTRK1IGF1R
SCHEMBL10312199 0.81 FLT3 (0.45) FLT3GSK3AGSK3BAURKAGRK6
SCHEMBL10312123 0.79 MELK (0.45) FLT3AURKAGRK6ABL1LCK
SCHEMBL16556920 0.79 IGF1R (0.46) FLT3NTRK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 FLT3 152/4885GSK3A 315/4885GSK3B 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.